Pandia: Gold Nanorods and Their Applications in Cancer Therapy and In Vivo Imaging in Companion Animals and Their Potential Application to Humans - Nanotechnology for Biomedical Imaging and Diagnostics - page 350

4. Further, Maltzahn et al. tested the prediction that a single dose of PeG-NRs
could destroy tumors. In this analysis, nude mice bearing bilateral human
MdA-MB-435 tumors were injected with either PeG-NRs or saline. After
72 h, the right flank of each mouse was irradiated for 5 min (810 nm, 2 W/cm 2 ),
and all tumors were measured at regular intervals over time. All irradiated,
PeG-NR-targeted tumors completely disappeared by external observation
within 10 days, whereas all other tumors, including those exposed to laser after
saline injection, continued to grow uninhibited. To assess the survival benefit
of PeG-NR-directed tumor ablation, mice bearing a single MdA-MB-435
tumor were divided between four cohorts (PeG-NRs + laser, PeG-NRs − laser,
saline + laser, saline − laser), and all tumors were measured over time. By 20
days after treatment, all irradiated, PeG-NR-injected mice displayed only a
minor scar with no evidence of tumor regrowth, whereas all other surviving
mice harbored thriving tumors. Over the course of greater than 50 days of
observation, no irradiated, PeG-NR-injected mice showed evidence of recur-
rence, whereas all mice in the control had to be euthanized by day 33. Body
weights of PeG-NR-treated mice were monitored over time and showed no
obvious losses due to tumor ablation and resorption.

12.3.2 nanopartz nanorod mouse Biodistribution

By using the ePR effect, gold nanoparticles can passively and selectively concentrate
in cancer tumors upward of 7% injected dose (Id)/g (refer to Table 12.1).

12.3.3 canine Toxicology evaluation

It is critical to the success of the platform as a potential therapy for cancer in
companion animals to establish the safety of this device. Thus, in 2010, Nanopartz
funded a research study by CARe Research LLC (Ft. Collins, CO), entitled
“Non-GLP Single dose (IV Slow Bolus) dose escalation (Up to 5 escalations

TaBle 12.1 Biodistribution data from mouse
injected Gold nanorods a

Tissue % Id/g tissue Standard deviation

Tumor 7.1 ±2.9

Brain 0.5 ±0.3

Bladder 0.4 ±0.1

Muscle 1.7 ±0.8

heart 2.4 ±0.9

Lung 4.4 ±0.9

Kidney 4.0 ±0.3

Liver 14.0 ±4.0

Spleen 51.9 ±13.0

a From Ref. [16].